Posted on 25th November 2014
Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.
It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.
04th October 2018
Cameron Optometry is an award-winning optometry practice and eyewear boutique, based in Edinburgh’s New Town. The practice is growing and is soon to open another consulting room, as such we are look...Read more
02nd October 2018
Great news! Cameron Optometry has been shortlisted for the UK Optical Team of the Year category at the AOP Awards. This is a real honour as the award recognises an optical team dedicated to deliv...Read more